Novare Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $263K | Sell |
4,340
-315
| -7% | -$18.4K | 0.02% | 172 |
|
|
2025
Q4 | $251K | Hold |
4,655
| – | – | 0.02% | 176 |
|
|
2025
Q3 | $210K | Sell |
4,655
-750
| -14% | -$35K | 0.02% | 188 |
|
|
2025
Q2 | $250K | Sell |
5,405
-845
| -14% | -$41.5K | 0.02% | 180 |
|
|
2025
Q1 | $381K | Hold |
6,250
| – | – | 0.03% | 146 |
|
|
2024
Q4 | $354K | Buy |
6,250
+1,325
| +27% | +$74K | 0.03% | 151 |
|
|
2024
Q3 | $255K | Buy |
4,925
+100
| +2% | +$4.69K | 0.02% | 170 |
|
|
2024
Q2 | $200K | Sell |
4,825
-1,005
| -17% | -$45K | 0.02% | 184 |
|
|
2024
Q1 | $316K | Buy |
5,830
+1,850
| +46% | +$94.2K | 0.03% | 146 |
|
|
2023
Q4 | $204K | Sell |
3,980
-500
| -11% | -$26.2K | 0.02% | 166 |
|
|
2023
Q3 | $260K | Sell |
4,480
-188
| -4% | -$11.5K | 0.03% | 148 |
|
|
2023
Q2 | $299K | Buy |
4,668
+50
| +1% | +$3.35K | 0.03% | 150 |
|
|
2023
Q1 | $320K | Sell |
4,618
-1,480
| -24% | -$104K | 0.04% | 143 |
|
|
2022
Q4 | $439K | Sell |
6,098
-5,252
| -46% | -$396K | 0.05% | 130 |
|
|
2022
Q3 | $807K | Sell |
11,350
-420
| -4% | -$30.5K | 0.1% | 102 |
|
|
2022
Q2 | $906K | Sell |
11,770
-101,710
| -90% | -$7.75M | 0.11% | 98 |
|
|
2022
Q1 | $8.29M | Sell |
113,480
-31
| -0% | -$2.08K | 0.88% | 46 |
|
|
2021
Q4 | $7.08M | Sell |
113,511
-1,540
| -1% | -$90.3K | 0.72% | 64 |
|
|
2021
Q3 | $6.81M | Buy |
115,051
+1,061
| +0.9% | +$69.9K | 0.76% | 66 |
|
|
2021
Q2 | $7.62M | Buy |
113,990
+3,471
| +3% | +$226K | 0.85% | 57 |
|
|
2021
Q1 | $6.98M | Buy |
110,519
+1,627
| +1% | +$101K | 0.84% | 56 |
|
|
2020
Q4 | $6.75M | Sell |
108,892
-1,170
| -1% | -$71.9K | 0.88% | 53 |
|
|
2020
Q3 | $6.64M | Sell |
110,062
-986
| -0.9% | -$59.3K | 0.93% | 43 |
|
|
2020
Q2 | $6.53M | Sell |
111,048
-295
| -0.3% | -$17.6K | 0.98% | 40 |
|
|
2020
Q1 | $6.21M | Buy |
111,343
+9,465
| +9% | +$579K | 1.09% | 33 |
|
|
2019
Q4 | $6.54M | Buy |
101,878
+4,995
| +5% | +$286K | 0.91% | 45 |
|
|
2019
Q3 | $4.91M | Buy |
96,883
+21,754
| +29% | +$1.02M | 0.73% | 64 |
|
|
2019
Q2 | $3.41M | Buy |
75,129
+11,049
| +17% | +$515K | 0.52% | 74 |
|
|
2019
Q1 | $3.06M | Buy |
64,080
+9,850
| +18% | +$491K | 0.48% | 75 |
|
|
2018
Q4 | $2.82M | Sell |
54,230
-34
| -0.1% | -$1.83K | 0.51% | 74 |
|
|
2018
Q3 | $3.04M | Hold |
54,264
| – | – | 0.48% | 74 |
|
|
2018
Q2 | $3M | Buy |
54,264
+11,830
| +28% | +$639K | 0.51% | 74 |
|
|
2018
Q1 | $2.68M | Buy |
42,434
+4,210
| +11% | +$271K | 0.47% | 78 |
|
|
2017
Q4 | $2.34M | Sell |
38,224
-1,555
| -4% | -$97.3K | 0.4% | 85 |
|
|
2017
Q3 | $2.54M | Buy |
+39,779
| New | +$2.32M | 0.45% | 84 |
|
|
2016
Q1 | – | Sell |
-4,687
| Closed | -$322K | – | 113 |
|
|
2015
Q4 | $322K | Sell |
4,687
-125
| -3% | -$8.26K | 0.09% | 103 |
|
|
2015
Q3 | $285K | Buy |
+4,812
| New | +$305K | 0.08% | 108 |
|
Other funds holding BMY
VCM
VPM
Novare Capital Management's BMY Position: Q1 2026 in Review
Novare Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 6.8% in Q1 2026, selling an estimated $18.4K and leaving 4,340 shares worth $263K. The position accounts for 0.02% of the portfolio, ranked #172.
Novare Capital Management first reported a position in BMY in Q3 2015 and has held it in 37 quarters since. The position peaked at $8.29M in Q1 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Novare Capital Management held 4,340 shares of Bristol-Myers Squibb worth $263K as of Q1 2026.
- Novare Capital Management sold 315 Bristol-Myers Squibb shares in Q1 2026, an estimated $18.4K.
- Bristol-Myers Squibb made up 0.02% of Novare Capital Management's portfolio in Q1 2026, its #172 holding.
- Novare Capital Management first reported a position in Bristol-Myers Squibb in Q3 2015 and has held it in 37 quarters since.
- Novare Capital Management's Bristol-Myers Squibb position peaked at $8.29M in Q1 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Novare Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.